Ingevity (NGVT) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
17 Jan, 2026Executive summary
Q3 2024 net sales were $376.9 million, down 16% year-over-year, mainly due to Performance Chemicals repositioning, lower industrial demand, and weather-related impacts.
Net loss for Q3 2024 was $107.2 million, driven by $86.9 million in restructuring charges, a $100 million CTO contract termination, and a $349.1 million goodwill impairment in Performance Chemicals.
Adjusted EBITDA was $106.4 million (28.2% margin), down 3.6% year-over-year, with gross margin up 610 basis points due to a shift toward higher-margin businesses.
Performance Materials and Advanced Polymer Technologies segments delivered sales growth and margin improvements, while Performance Chemicals saw significant repositioning and operational declines.
Major restructuring included plant closures, workforce reductions, and exit from lower-margin markets, with $18 million in Q3 savings and $65–$75 million in 2024 savings expected.
Financial highlights
Free cash flow was $28.5 million, including a $50 million CTO contract termination payment and $21 million in restructuring charges.
Net leverage ratio was 4.0x, with expectations to reach 3.5x by year-end; bank-calculated leverage at 3.0x.
Adjusted diluted EPS was $1.10, down 9.1% year-over-year; basic and diluted EPS for Q3 2024 was $(2.95).
Cash and cash equivalents at quarter-end were $135.5 million.
Capital expenditures for nine months were $52.7 million; full-year projected at $90–$100 million.
Outlook and guidance
Full-year 2024 sales expected at the lower end of $1.40–$1.50 billion, with Adjusted EBITDA between $350–$360 million.
Performance Chemicals repositioning expected to yield $95–$110 million in annualized cash savings, with $65–$75 million realized in 2024.
Priorities include improved execution, leverage reduction, and a portfolio review, with a target of $400 million EBITDA and leverage around 3x by year-end 2025.
Free cash flow expected to remain positive despite contract termination payments.
Key uncertainties include global industrial recovery, geopolitical risks, U.S. election dynamics, and auto production pace.
Latest events from Ingevity
- Strategic transformation, board refreshment, and strong financial and ESG performance drive key proposals.NGVT
Proxy Filing17 Mar 2026 - Board recommends approval of all proposals, including director elections and incentive plan changes.NGVT
Proxy Filing17 Mar 2026 - Adjusted EBITDA margin rose to 31.9%, free cash flow reached $274M, and leverage improved to 2.6x.NGVT
Q4 202526 Feb 2026 - Q2 net loss of $283.7M on $390.6M sales, with major goodwill impairment and restructuring.NGVT
Q2 20242 Feb 2026 - Record Performance Materials results and strong cash flow drive improved 2025 outlook.NGVT
Q4 202426 Dec 2025 - Sharpened focus on core segments, divestitures, and strong cash returns drive growth and value.NGVT
Investor Update15 Dec 2025 - Global leader in sustainable materials, with $1.2B revenue and 31.4% EBITDA margin in 2024.NGVT
Investor Presentation8 Dec 2025 - Record financial results, board refreshment, and key votes amid a contested director election.NGVT
Proxy Filing1 Dec 2025 - Leadership overhaul, portfolio optimization, and strong governance drive 2024 transformation.NGVT
Proxy Filing1 Dec 2025